Drug particle aggregation

Drug particle aggregation is a physicochemical phenomenon in which drug molecules, particularly biopharmaceuticals such as monoclonal antibodies or recombinant proteins, associate to form larger clusters, oligomers, or precipitates. This process is primarily driven by hydrophobic interactions, electrostatic forces, or covalent bonding and can occur during manufacturing, storage, or administration due to mechanical stress, temperature changes, or pH shifts (Cromwell et al., 2006, AAPS J). In the context of drug development, aggregation is considered a major hurdle rather than a therapeutic target, as it often leads to the degradation of the drug's potency and shelf-life. Clinically, aggregated particles are highly problematic because they can act as adjuvants that stimulate the patient's immune system, leading to the formation of anti-drug antibodies (ADAs) that neutralize the drug or cause severe allergic reactions (Moussa et al., 2016, J. Pharm. Sci.). Consequently, maintaining low levels of drug particle aggregation is a critical quality control parameter enforced by regulatory agencies like the FDA to ensure patient safety and drug stability.

Other names

Protein aggregationDrug self-associationParticulate formationPhysical instabilityFormulation aggregation

Not applicable as this is a formulation stability issue, not a therapeutic mechanism.